524 related articles for article (PubMed ID: 25879041)
1. Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
Hou H; Hu S; Fan R; Sun W; Zhang X; Tian M
Biomed Res Int; 2015; 2015():974689. PubMed ID: 25879041
[TBL] [Abstract][Full Text] [Related]
2.
Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
[TBL] [Abstract][Full Text] [Related]
3. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease.
Zantut-Wittmann DE; Ramos CD; Santos AO; Lima MM; Panzan AD; Facuri FV; Etchebehere EC; Lima MC; Tambascia MA; Camargo EE
Nucl Med Commun; 2005 Nov; 26(11):957-63. PubMed ID: 16208172
[TBL] [Abstract][Full Text] [Related]
4. Influence of (99m)Tc-pertechnetate thyroid imaging on radioactive iodine uptake.
Guo N; Yang K; Lin YS; Wang T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):267-70. PubMed ID: 24997818
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
[TBL] [Abstract][Full Text] [Related]
6. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
7. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
8. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.
Uchida T; Suzuki R; Kasai T; Onose H; Komiya K; Goto H; Takeno K; Ishii S; Sato J; Honda A; Kawano Y; Himuro M; Yamada E; Yamada T; Watada H
Endocr J; 2016; 63(2):143-9. PubMed ID: 26581846
[TBL] [Abstract][Full Text] [Related]
9. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
10. Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging.
Oki GC; Zantut-Wittmann DE; de Oliveira Santos A; Guariento MH; Tambascia MA; de Almeida EA; Amorim BJ; Lima MC; Etchebehere EC; Camargo EE; Ramos CD
Clin Nucl Med; 2010 Apr; 35(4):223-7. PubMed ID: 20305407
[TBL] [Abstract][Full Text] [Related]
11. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
[TBL] [Abstract][Full Text] [Related]
13. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
14.
Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
[TBL] [Abstract][Full Text] [Related]
15. The key role of newborn thyroid scintigraphy with isotopic iodide (123I) in defining and managing congenital hypothyroidism.
Schoen EJ; Clapp W; To TT; Fireman BH
Pediatrics; 2004 Dec; 114(6):e683-8. PubMed ID: 15574601
[TBL] [Abstract][Full Text] [Related]
16. Strategies of radioiodine therapy for Graves' disease.
Lind P
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
[TBL] [Abstract][Full Text] [Related]
17. Thyroid blood flow and uptake of technetium-99m pertechnetate in Graves' disease.
Sekulić V; Rajić M; Vlajković M; Ilić S; Bogićević M; Antić S; Dimić D
Hell J Nucl Med; 2006; 9(3):173-6. PubMed ID: 17160158
[TBL] [Abstract][Full Text] [Related]
18. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound.
Meller J; Becker W
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S425-38. PubMed ID: 12192542
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical exacerbation of preexisting Graves' disease induced by insufficient radioiodine treatment: a report of five patients.
Lee SW; Lee J; Bae JH; Seo JH; Kang SM; Ahn BC; Lee I
Nucl Med Commun; 2009 Apr; 30(4):275-80. PubMed ID: 19252454
[TBL] [Abstract][Full Text] [Related]
20. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
